Abstract
Amniotic fluid embolism (AFE) continues to pose a formidable clinical challenge with its high rate of morbidity and mortality. A novel biomarker that acts as an early warning system for the clinician would be a welcomed addition to our medical armamentarium. Here we review the state of diagnosing AFE with our current methods of evaluation and testing along with recently discovered potential biomarkers that may be clinically efficacious. Additionally we explore the future of proteomics, lipidomics, and transcriptomics as tools to identify potential novel signaling pathways and biomarkers.
Keywords: Amniotic fluid embolism, biomarkers, diagnosis, management, proteomics, transcriptomics.
Current Pharmaceutical Biotechnology
Title:Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Volume: 14 Issue: 14
Author(s): Stanislaw P. Stawicki and Thomas J. Papadimos
Affiliation:
Keywords: Amniotic fluid embolism, biomarkers, diagnosis, management, proteomics, transcriptomics.
Abstract: Amniotic fluid embolism (AFE) continues to pose a formidable clinical challenge with its high rate of morbidity and mortality. A novel biomarker that acts as an early warning system for the clinician would be a welcomed addition to our medical armamentarium. Here we review the state of diagnosing AFE with our current methods of evaluation and testing along with recently discovered potential biomarkers that may be clinically efficacious. Additionally we explore the future of proteomics, lipidomics, and transcriptomics as tools to identify potential novel signaling pathways and biomarkers.
Export Options
About this article
Cite this article as:
Stawicki P. Stanislaw and Papadimos J. Thomas, Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research, Current Pharmaceutical Biotechnology 2013; 14 (14) . https://dx.doi.org/10.2174/1389201015666140430163921
DOI https://dx.doi.org/10.2174/1389201015666140430163921 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Hydrogels: A Journey from Diapers to Gene Delivery
Mini-Reviews in Medicinal Chemistry Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Decoding the Transcriptional Response to Ischemic Stroke in Obese and Non-obese Mice Brain
Current Neurovascular Research New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle
Current Pharmaceutical Design Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Current Enzyme Inhibition MicroRNAs and Cardiac Conduction
Current Drug Targets Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry